Cheryl Gault, Chief Executive Officer at Rapport Therapeutics, Inc. (RAPP), sold 2,210 shares at $29.16 ($64K) on 2026-10-21, disclosed to the SEC on 2026-10-23.
Scheduled sale ($64k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| RAPP | BUY | 2026-10-22 | $974K | — | Filing → |
| RAPP | BUY | 2026-10-22 | $100K | — | Filing → |
| RAPP | BUY | 2026-10-22 | $249K | — | Filing → |